3D printed drugs are gaining popularity on account of their benefits to not only the consumer but also to the drug/ pharma manufacturing companies. The drugs manufacturing companies are inclined and adopting additive manufacturing technology to their production unit for purposes such as reduce costs, mass production, and personalized medicine as well. Moreover, 3D printed drugs are driving the pharmaceutical industry towards personalized medicine. Moreover, the surging prevalence of dysphagia is contributing to the growing demand for the personalized medicines. In the general population of 29 years to 32 years, the prevalence of dysphagia is around 16-23% which is increasing to 27% in those over 76 years of age. Also, 50% of people have difficulties during pill intake, As revealed by PMLiVE. The difficulty in pill intake is because of the size and shape of the medicine. Therefore, companies had started producing personalized medicine in different sizes, shapes, and dosage.
The government across the countries are investing in 3D printing projects. In 2020, the government of Australia along with and the state of Lower Austria have launched two funding packages for digital technologies including 3D printing. Also, the government of the United Kingdom invested USD 920.40 in 2010 for technologies including 3D printing as well. Also, the COVID-19 pandemic gave a robust growth to the 3D printed drugs market owing to the shortage of medicine. As per the U.S National Library of Medicine National Institute of Health, Medication shortages in 2020 have reached 87% that of the shortages reported in 2019 in half of the time.
Based on the technology, the 3D printed drugs market is bifurcated into Inkjet printing, Fused deposition modeling, Stereolithography, and others. The Inkjet printing segment generated revenue of US$ 269.7 million in 2019. The market for the Inkjet printing segment is expected to grow at a CAGR of 16.6% during the forecast period to reach a market valuation of US$ 954.1 million by 2027. However, Stereolithography Market is expected to witness substantial growth during the forecast period 2021-2027.
Based on the application type, the 3D printed drugs market is fragmented into Orthopedic, Neurology, Hearing & Audibility Aid, Medical Implants, Dental, and Others. The neurology segment generated revenue of US$ 224.2 million in 2019. The market is expected to grow at a CAGR of 16.2% during the forecast period to reach a market valuation of US$ 775.7 million by 2027.
Based on drug form, the 3D printed drugs market is fragmented into Tablet, Capsules, Multi-Drug Implants, Nanoparticles, Solutions, Nano Suspension, Encapsulated within a polymer and Implant. The Tablet segment generated revenue of US$ 190.5 million in 2019. The market is expected to grow at a CAGR of 16.3% during the forecast period to reach a market valuation of US$ 663.4 million by 2027.
Based on the drug, the 3D printed drugs market is fragmented into Spritam and Others. The Spritam segment generated revenue of US$ 416.3 million in 2019. The market is expected to grow at a CAGR of 12.8% during the forecast period to reach a market valuation of US$ 1142.9 million by 2027. However, the other segment would proliferate with the highest CAGR during the forthcoming years.
Based on end-users, the 3D printed drugs market is fragmented into Hospitals, Clinics, and Research Laboratories. The hospital segment generated revenue of US$ 204.8 million in 2019. The market is expected to grow at a CAGR of 15.6 % during the forecast period to reach a market valuation of US$ 680.7 billion by 2027. However, the research laboratories segment is expected to witness the highest CAGR during the forecast period.
For a better understanding of the market penetration of 3D printed drugs, the market is analyzed based on its worldwide presence in the countries such as North America (US, Canada, Rest of North America), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South-Korea, and Rest of Asia-Pacific), and Rest of the world. North America constitutes a major market for 3D printed medicine.
Some of the major players operating in the market include Aprecia Pharmaceuticals, LLC., GlaxoSmithKline plc, AstraZeneca, FabRx Ltd., Hewlett Packard Caribe, Merck KGaA, Cycle Pharmaceuticals, and Tvasta.
The global 3D printed drugs market was valued at US$ 638.6 million in 2019 and is projected to expand significantly with a CAGR of 15.24 % from 2021 to 2027. The global 3D printed drugs market is expected to witness a boost, owing to the surging prevalence of dysphagia, rising investment in healthcare technologies, and the surging demand for the personalized medicines.
The global 3D printed drugs market is witnessing an uptick on account of the government's investment in the 3D printing technology, raising venture capital for 3D printing startups, and the investment by the pharma companies in 3D printing technology. In a study, it was found that around 63% of the pharma companies are thinking of investing in 3D printing technology and the number of professionals using 3D printing technology was 3 times higher than that of 3 years ago which was in 2017. The Venture capital funding for 3D printing is also one of the most prominent reasons for market growth. Furthermore, the state of Lower Austria and the Austrian federal government together announced two funding packages in 2020 which will support investments in advanced digital technologies, including 3D printing.
Moreover, the surging prevalence of chronic disease and the rising number of patients globally generating the demand for soluble drugs, due to which the demand for personalized 3D printed medicine is emerging. In a study, it was found that Dysphagia affects approximately 9 million adults per year in the United States and is especially prevalent among the elderly. Characteristically, 50-75% of stroke patients and 60-70% of patients who undergo radiation therapy for head and neck cancer have dysphagia. The government across countries is investing more in healthcare and more emphasis on 3D printing technology for quick production owing to the surging need globally. As per OCED, the government in the United States spend USD 8,032.6 USD per capita in 2015 that increased to USD 9,386.5 USD per capita in 2019 same way in the U.K the government spent 3,043.6 USD per capita in 2015 that increased to USD 3619.5 USD per capita in 2019.
Also, surging government's emphasis on personalized medicine and the rising end-user's awareness about the medicine as per individual's need coupled with the benefits such as high dose in single tablet, swallowable, and different form of drugs is generating the demand for the 3D printed drugs so, the market is promulgating.
The global 3D Printed Drugs market is highly fragmented. The availability of numerous global and local players across regions makes the industry highly competitive. The key players with a considerable market share in the industry are GlaxoSmithKline plc., Aprecia Pharmaceuticals, LLC., AstraZeneca, FabRx Ltd, Merck KGaA, Cycle Pharmaceuticals, Tvasta, MSD, etc. Several M&A's along with partnerships have been undertaken by these players to facilitate costumers with hi-tech and innovative products.
Insights Presented in the Report
"Amongst technology, inkjet printing segment holds the major share"
Based on product type, the market is fragmented into inkjet printing, fused deposition modeling, stereolithography, and others. The inkjet printing segment dominated the market with a share of 42.2% in 2019 and is expected to maintain its dominance during the forecast period on account of the benefits such as low cost, programmability, high resolution, high throughput, high speed, and biocompatibility of these printers and the launch of new products by the key players in the industry.
"Amongst applications, neurology is expected to dominate the market during the analyzed period"
Based on the applications market is segmented into Orthopedic, Neurology, Hearing & Audibility Aid, Medical Implants, Dental, and others. In 2019, the neurology segment grabbed the major market share and accounted for 35.1% of the market revenue share. The surging prevalence of the neurological disorder is leading to the growing share of this segment. In a study, it was found that Neurological disorders are the number one cause of disability globally and around 1 billion people throughout the world are affected by some type of neurological disease. Moreover, the orthopedic segment is expected to grow with a CAGR of more than 15.9% during the forecast period of 2021-27.
"Amongst drug form, the tablet is expected to dominate the market during the analyzed period"
Based on the drug form, the market is segmented into the tablet, capsules, multidrug implants, nanoparticles, solutions, nanosuspension, encapsulated within a polymer, and others. In 2019, the tablet segment grabbed the major market share and accounted for 29.8% of the market revenue share. The properties of tablets such as longer shelf life, variety of forms. Also, it accommodates a higher dose of an active ingredient than a capsule. Moreover, the capsule segment is expected to grow with a CAGR of more than 15.8% during the forecast period of 2021-27.
"North America represents one of the largest markets of the 3D Printed Drugs market"
For a better understanding of the market dynamics of the 3D Printed Drugs market, a detailed analysis was conducted for different regions across the globe including North America (the U.S, Canada, and the Rest of North America), Europe (Germany, France, Italy, United Kingdom, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of APAC) and Rest of the World has been conducted. North America dominated the market and generated revenue of US$ 306.8 million in 2019 owing to the escalating healthcare IT investment in the countries such as the U.S and Canada. Moreover, the presence of well-established players in additive manufacturing makes the region dominant across the globe.
Reasons to buy this report:
? The study includes market sizing and forecasting analysis validated by authenticated key industry experts
? The report presents a quick review of overall industry performance at one glance
? The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments
? Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry
? The study comprehensively covers the market across different segments
? Deep dive regional level analysis of the industry
Customization Options:
The 3D Printed Drugs market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.
Table of Contents
1 MARKET INTRODUCTION
1.1 Market Definitions
1.2 Objective of the Study
1.3 Limitation
1.4 Stake Holders
1.5 Currency Used in Report
1.6 Scope of the Global 3D Printed Drugs Market Study
2 RESEARCH METHODOLOGY OR ASSUMPTION
2.1 Research Methodology for the Global 3D Printed Drugs Market
2.1.1 Main Objective of the Global 3D Printed Drugs Market
3 INDUSTRY PERFORMANCE
4 EXECUTIVE SUMMARY
5 CASE STUDIES
6 COVID-19 IMPACT
7 MARKET INSIGHTS BY TECHNOLOGY
7.1 Inkjet Printing
7.2 Fused Deposition Modelling
7.3 Stereolithography
7.4 Others
8 MARKET INSIGHTS BY APPLICATION
8.1 Orthopaedic
8.2 Neurology
8.3 Hearing & Audibility Aid
8.4 Medical Implants
8.5 Dental
8.6 Others
9 MARKET INSIGHTS BY DRUG FORM
9.1 Tablets
9.2 Capsules
9.3 Multi Drug Implants
9.4 Nano Particles
9.5 Solutions
9.6 Nano Suspension
9.7 Encapsulated within a Polymer
9.8 Implant
10 MARKET INSIGHTS BY DRUG
10.1 Spritam
10.2 Others
11 MARKET INSIGHTS BY END-USER
11.1 Hospitals
11.2 Clinics
11.3 Research Laboratories
12 MARKET INSIGHTS BY REGION
12.1 North America 3D Printed Drugs Market
12.1.1 US
12.1.2 Canada
12.1.3 Rest of North America
12.2 Europe 3D Printed Drugs Market
12.2.1 United Kingdom
12.2.2 France
12.2.3 Germany
12.2.4 Spain
12.2.5 Italy
12.2.6 Rest of Europe
12.3 Asia Pacific 3D Printed Drugs Market
12.3.1 China
12.3.2 India
12.3.3 Japan
12.3.4 Australia
12.3.5 South Korea
12.3.6 Rest of Asia Pacific
12.4 Rest of the World 3D Printed Drugs Market
13 3D PRINTED DRUGS MARKET DYNAMICS
13.1 Market Drivers
13.2 Market Challenges
13.3 Impact Analysis
14 LEGAL & REGULATORY FRAMEWORK
15 DEMAND AND SUPPLY SIDE ANALYSIS
15.1 Demand Side Analysis
15.2 Supply Side Analysis
15.2.1 Top Product Launches
15.2.2 Top Business Partnerships
15.2.3 Top Merger & Acquisitions
15.2.4 Top Business Expansions and Investments
16 VALUE CHAIN ANALYSIS
17 3D PRINTED DRUGS MARKET HOTSPOT & OPPORTUNITIES
18 3D PRINTED DRUGS MARKET TRENDS & INSIGHTS
19 COMPETITIVE SCENARIO
19.1 Porter's Five forces analysis
19.1.1 Bargaining power of Supplier
19.1.2 Bargaining power of Buyer
19.1.3 Industry Rivalry
19.1.4 Availability of Substitute
19.1.5 Threat of new Entrants
19.2 Competitive Landscape
19.2.1 Company Shares, By Revenue
19.3 Competition Matrix
19.3.1 Product/Service Portfolio
19.3.2 Target Markets
19.3.3 Target End Users
19.3.4 Research and Developments
GlaxoSmithKline plc.
Aprecia Pharmaceuticals
LLC.
AstraZeneca
FabRx Ltd
Merck KGaA
Hewlett Packard Caribe
Cycle Pharmaceuticals
Tvasta